Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

LaMontagne will lead the commercial rollout of the company’s groundbreaking early-stage cancer detection test, Certitude.

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

Colonoscopy prevalence increased from 19.5% in 2019 and 17.8% in 2021 to 27.7% in 2023, while stool-based testing increased ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago. These ...

Review quarterly and annual revenue, net income, and cash flow for Exact Sciences Corp (EXAS:XNAS) stock through the last fiscal year.

Matt Ryan is once again heating up the topic of the Assassin's Creed IV: Black Flag remake. Although he avoided clear answers ...

Check out our EXAS stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.